Chest
Volume 142, Issue 4, Supplement, October 2012, Page 1027A
Journal home page for Chest

Signs and Symptoms of Chest Diseases | October 2012
Riociguat for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (PATENT-1)

https://doi.org/10.1378/chest.1462799Get rights and content

Section snippets

Abstract

SESSION TYPE: Late-Breaking Abstracts

PRESENTED ON: Tuesday, October 23, 2012 at 04:30 PM - 05:45 PM

PURPOSE: Riociguat is the first member of a novel class of compounds, the soluble guanylate cyclase (sGC) stimulators. With a dual mode of action, it synergizes with endogenous nitric oxide (NO) and also directly stimulates sGC independent of NO availability. Therefore, riociguat may restore the NO-sGC-cGMP pathway. The Phase III, double-blind, randomized, placebo-controlled PATENT-1 study

References (0)

Cited by (0)

View full text